肿瘤细胞治疗研究
英文原题：Novel CAR T-cell therapies for relapsed/refractory B-cell malignancies: latest updates from 2023 ASH annual meeting.
嵌合抗原受体（CAR）是工程化融合蛋白，可将 T 细胞靶向肿瘤细胞的特定表面抗原，从而产生有效的抗肿瘤应答。
嵌合抗原受体（CAR）是经工程化改造的融合蛋白，可将T细胞靶向肿瘤细胞特定表面抗原，从而诱导有效抗肿瘤应答。CAR-T细胞疗法在复发/难治性B细胞恶性肿瘤（R/R BCM）治疗中的作用日益重要。为使CAR-T细胞治疗R/R BCM更安全有效，多种新型工程化CAR-T药物目前处于研发或临床试验阶段。本文总结了2023年ASH年会上报告的R/R BCM新型CAR-T疗法最新研究，以及相关临床试验的最新进展。
Chimeric antigen receptors (CAR) are engineered fusion proteins that target T-cells to specific surface antigens of tumor cells to generate effective anti-tumor responses. CAR T-cell therapy is playing an increasingly important role in the treatment of relapsed/refractory B-cell malignancies (R/R BCM). Attempting to make CAR T-cells safer and more effective in treating R/R BCM, various novel engineered CAR T-cell agents are currently in the research and development or clinical trial stages. We have summarized here the latest reports on the novel CAR T-cell therapies for R/R BCM presented at the 2023 ASH Annual Meeting as well as the latest updates in related clinical trials.
MEMBER ACCOUNT
登录成功会直接打开下一页。
